These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 18201402)

  • 1. Cervical screening: why young women should be encouraged to be screened.
    Herbert A; Holdsworth G; Kubba AA
    J Fam Plann Reprod Health Care; 2008 Jan; 34(1):21-5. PubMed ID: 18201402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasive cervical cancer audit: why cancers developed in a high-risk population with an organised screening programme.
    Herbert A; Anshu ; Culora G; Dunsmore H; Gupta SS; Holdsworth G; Kubba AA; McLean E; Sim J; Raju KS
    BJOG; 2010 May; 117(6):736-45. PubMed ID: 20184570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of screening episodes linked to CIN3 and invasive cancer registrations to study outcomes from the NHS Cervical Screening Programme.
    Blanks RG; Moss SM; Coleman DA; Addou S; Swerdlow AJ
    Cytopathology; 2009 Jun; 20(3):154-60. PubMed ID: 19207309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cervical intraepithelial neoplasia grade III (CIN III) and invasive cervical carcinoma: the yawning gap revisited and the treatment of risk.
    Herbert A; Smith JA
    Cytopathology; 1999 Jun; 10(3):161-70. PubMed ID: 10390064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensified screening among high risk women within the organised screening programme for cervical cancer in Finland.
    Kotaniemi-Talonen L; Malila N; Anttila A; Nieminen P; Hakama M
    Acta Oncol; 2011 Jan; 50(1):106-11. PubMed ID: 20560860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
    Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
    Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
    BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How many cervical cancers are prevented by treatment of screen-detected disease in young women?
    Sasieni P; Castanon A; Parkin DM
    Int J Cancer; 2009 Jan; 124(2):461-4. PubMed ID: 18844220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive cervical cancer audit: a relative increase in interval cancers while coverage increased and incidence declined.
    Herbert A; Anshu ; Gregory M; Gupta SS; Singh N
    BJOG; 2009 May; 116(6):845-53. PubMed ID: 19432575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks of cervical intraepithelial neoplasia grade 3 or invasive cancers in ASCUS women with different management: a population-based cohort study.
    Tai YJ; Chen YY; Hsu HC; Chiang CJ; You SL; Chen CA; Cheng WF;
    J Gynecol Oncol; 2018 Jul; 29(4):e55. PubMed ID: 29770625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dramatic increase in cervical cancer registrations in young women in 2009 in England unlikely to be due to the new policy not to screen women aged 20-24.
    Sasieni P; Castanon A
    J Med Screen; 2012 Sep; 19(3):127-32. PubMed ID: 23093730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme.
    Anttila A; Kotaniemi-Talonen L; Leinonen M; Hakama M; Laurila P; Tarkkanen J; Malila N; Nieminen P
    BMJ; 2010 Apr; 340():c1804. PubMed ID: 20423964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-grade squamous intraepithelial lesion in women aged <30 years has a prevalence pattern resembling low-grade squamous intraepithelial lesion.
    Vale DB; Westin MC; Zeferino LC
    Cancer Cytopathol; 2013 Oct; 121(10):576-81. PubMed ID: 23765869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of the referral outcome diagram and an analysis of laboratory cancer detection rates in the English NHS cervical screening programme--is there an optimum level of detection of CIN 1 and CIN 2 lesions?
    Blanks RG
    Cytopathology; 2008 Aug; 19(4):244-53. PubMed ID: 18476989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational care or rationing care? The case of cervical screening across the United Kingdom.
    Flynn H; Lewis P
    Health Policy; 2013 Oct; 112(3):197-201. PubMed ID: 23910733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical screening in 20-24-year olds.
    Rieck GC; Tristram A; Hauke A; Fielder H; Fiander AN
    J Med Screen; 2006; 13(2):64-71; discussion 62-3. PubMed ID: 16792827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
    Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.